Quanterix (NASDAQ:QTRX) Announces Earnings Results

Quanterix (NASDAQ:QTRX) posted its quarterly earnings data on Monday. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.63), FiscalAI reports. Quanterix had a negative net margin of 71.86% and a negative return on equity of 23.92%. The business had revenue of $32.91 million during the quarter, compared to analyst estimates of $37.46 million.

Quanterix Stock Performance

QTRX stock opened at $4.03 on Monday. The stock has a market capitalization of $189.85 million, a PE ratio of -1.71 and a beta of 1.07. The company has a fifty day moving average of $3.70 and a 200-day moving average of $4.20. Quanterix has a one year low of $2.39 and a one year high of $8.77.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on QTRX shares. Canaccord Genuity Group lowered their price target on Quanterix from $8.00 to $4.00 and set a “hold” rating on the stock in a report on Monday, April 20th. Wall Street Zen raised Quanterix from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen decreased their price objective on Quanterix from $7.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 7th. Finally, Weiss Ratings downgraded Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and an average target price of $4.00.

Institutional Investors Weigh In On Quanterix

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its holdings in Quanterix by 26.3% in the 1st quarter. Royal Bank of Canada now owns 170,745 shares of the company’s stock valued at $1,112,000 after purchasing an additional 35,509 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Quanterix by 204.4% during the 1st quarter. AQR Capital Management LLC now owns 98,990 shares of the company’s stock worth $644,000 after buying an additional 66,470 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Quanterix by 20.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company’s stock worth $2,277,000 after buying an additional 59,655 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Quanterix by 4.2% in the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock valued at $380,000 after buying an additional 2,366 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Quanterix by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 887,080 shares of the company’s stock valued at $5,900,000 after buying an additional 21,210 shares during the period. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.